Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 . SHENZHEN, CHINA, Jan 24, 2025 - (ACN News ...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 24 January ...

Authenticated data presented in the Respiratory Drugs market report is based on findings of extensive primary and secondary research ...

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.

Objectives To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared ...

The announcement that inhaled insulin will soon be available in India has understandably generated a lot of excitement and ...

Green: These inhalers tend to be for long-acting beta-agonist preventer medication, most often used to help reduce symptoms of respiratory conditions like asthma or COPD. These must also be taken ...

MACE incidence in patients with COPD initiating triple therapy was 11.3/100/year vs 8.7/100/year in patients using LABA-ICS. In patients with chronic obstructive pulmonary disease (COPD), the first ...